157 related articles for article (PubMed ID: 30858416)
1. Physical plasma-triggered ROS induces tumor cell death upon cleavage of HSP90 chaperone.
Bekeschus S; Lippert M; Diepold K; Chiosis G; Seufferlein T; Azoitei N
Sci Rep; 2019 Mar; 9(1):4112. PubMed ID: 30858416
[TBL] [Abstract][Full Text] [Related]
2. Sildenafil triggers tumor lethality through altered expression of HSP90 and degradation of PKD2.
Chen L; Liu Y; Becher A; Diepold K; Schmid E; Fehn A; Brunner C; Rouhi A; Chiosis G; Cronauer M; Seufferlein T; Azoitei N
Carcinogenesis; 2020 Oct; 41(10):1421-1431. PubMed ID: 31917403
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibitor-induced cleavage of HSP90 is mediated by ROS generation and caspase 10-activation in human leukemic cells.
Park S; Park JA; Yoo H; Park HB; Lee Y
Redox Biol; 2017 Oct; 13():470-476. PubMed ID: 28715732
[TBL] [Abstract][Full Text] [Related]
4. Vorinostat enhances gefitinib‑induced cell death through reactive oxygen species‑dependent cleavage of HSP90 and its clients in non‑small cell lung cancer with the EGFR mutation.
Park SE; Kim DE; Kim MJ; Lee JS; Rho JK; Jeong SY; Choi EK; Kim CS; Hwang JJ
Oncol Rep; 2019 Jan; 41(1):525-533. PubMed ID: 30365122
[TBL] [Abstract][Full Text] [Related]
5. HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment.
Guo A; Lu P; Lee J; Zhen C; Chiosis G; Wang YL
Oncogene; 2017 Jun; 36(24):3441-3449. PubMed ID: 28114285
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.
Giulino-Roth L; van Besien HJ; Dalton T; Totonchy JE; Rodina A; Taldone T; Bolaender A; Erdjument-Bromage H; Sadek J; Chadburn A; Barth MJ; Dela Cruz FS; Rainey A; Kung AL; Chiosis G; Cesarman E
Mol Cancer Ther; 2017 Sep; 16(9):1779-1790. PubMed ID: 28619753
[TBL] [Abstract][Full Text] [Related]
7. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C
Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595
[TBL] [Abstract][Full Text] [Related]
8. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2.
Gallerne C; Prola A; Lemaire C
Biochim Biophys Acta; 2013 Jun; 1833(6):1356-66. PubMed ID: 23485394
[TBL] [Abstract][Full Text] [Related]
9. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
Donnelly A; Blagg BS
Curr Med Chem; 2008; 15(26):2702-17. PubMed ID: 18991631
[TBL] [Abstract][Full Text] [Related]
10. PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy.
Li HK; Matsumoto Y; Furusawa Y; Kamada T
J Radiat Res; 2016 Sep; 57(5):572-575. PubMed ID: 27242340
[TBL] [Abstract][Full Text] [Related]
11. The flavonoid TL-2-8 induces cell death and immature mitophagy in breast cancer cells via abrogating the function of the AHA1/Hsp90 complex.
Liu HJ; Jiang XX; Guo YZ; Sun FH; Kou XH; Bao Y; Zhang ZQ; Lin ZH; Ding TB; Jiang L; Lei XS; Yang YH
Acta Pharmacol Sin; 2017 Oct; 38(10):1381-1393. PubMed ID: 28504248
[TBL] [Abstract][Full Text] [Related]
12. Andrographolide downregulates the v-Src and Bcr-Abl oncoproteins and induces Hsp90 cleavage in the ROS-dependent suppression of cancer malignancy.
Liu SH; Lin CH; Liang FP; Chen PF; Kuo CD; Alam MM; Maiti B; Hung SK; Chi CW; Sun CM; Fu SL
Biochem Pharmacol; 2014 Jan; 87(2):229-42. PubMed ID: 24161787
[TBL] [Abstract][Full Text] [Related]
13. [Molecular chaperone HSP90 as a novel target for cancer chemotherapy].
Miyata Y
Nihon Yakurigaku Zasshi; 2003 Jan; 121(1):33-42. PubMed ID: 12617036
[TBL] [Abstract][Full Text] [Related]
14. Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71.
Segawa T; Fujii Y; Tanaka A; Bando S; Okayasu R; Ohnishi K; Kubota N
Int J Mol Med; 2014 Mar; 33(3):559-64. PubMed ID: 24366006
[TBL] [Abstract][Full Text] [Related]
15. Hsp90 is cleaved by reactive oxygen species at a highly conserved N-terminal amino acid motif.
Beck R; Dejeans N; Glorieux C; Creton M; Delaive E; Dieu M; Raes M; Levêque P; Gallez B; Depuydt M; Collet JF; Calderon PB; Verrax J
PLoS One; 2012; 7(7):e40795. PubMed ID: 22848402
[TBL] [Abstract][Full Text] [Related]
16. The importance of being chaperoned: HSP90 and necroptosis.
Jacobsen AV; Silke J
Cell Chem Biol; 2016 Feb; 23(2):205-207. PubMed ID: 26971869
[TBL] [Abstract][Full Text] [Related]
17. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage.
Ha K; Fiskus W; Rao R; Balusu R; Venkannagari S; Nalabothula NR; Bhalla KN
Mol Cancer Ther; 2011 Jul; 10(7):1194-206. PubMed ID: 21566061
[TBL] [Abstract][Full Text] [Related]
18. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy.
Ying W; Du Z; Sun L; Foley KP; Proia DA; Blackman RK; Zhou D; Inoue T; Tatsuta N; Sang J; Ye S; Acquaviva J; Ogawa LS; Wada Y; Barsoum J; Koya K
Mol Cancer Ther; 2012 Feb; 11(2):475-84. PubMed ID: 22144665
[TBL] [Abstract][Full Text] [Related]
19. Plasma-induced selectivity in bone cancer cells death.
Canal C; Fontelo R; Hamouda I; Guillem-Marti J; Cvelbar U; Ginebra MP
Free Radic Biol Med; 2017 Sep; 110():72-80. PubMed ID: 28571751
[TBL] [Abstract][Full Text] [Related]
20. 17-DMAG induces heat shock protein 90 functional impairment in human bladder cancer cells: knocking down the hallmark traits of malignancy.
Karkoulis PK; Stravopodis DJ; Voutsinas GE
Tumour Biol; 2016 May; 37(5):6861-73. PubMed ID: 26662567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
